Vericel Corporation (NASDAQ:VCEL) is reporting third quarter earnings results on Thursday 5th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.02 per share from $ 31.06 million in revenue.
For the full year, analysts predict revenues of $ 122.03 million, while looking forward to loss of $ 0.11 per share.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 32.00 million ~ $ 32.00 million
Full Year 2020 topline are forecasted in a range of$ 141.00 million ~ $ 146.00 million
Click Here For More Historical Outlooks Of Vericel Corporation
Previous Quarter Performance
Vericel Corporation unveiled loss for the second quarter of $ 0.18 per share, from the revenue of $ 20.01 million. Street analysts expected Vericel Corporation to report loss of $ 0.21 per share on revenue of $ 18.87 million for the second quarter. The bottom line results beat street analysts by $ 0.03 or 14.29 percent, at the same time, top line results outshined analysts by $ 1.14 million or 6.04 percent.
Stock Performance
Shares of Vericel Corporation traded up $ 0.28 or 1.34 percent on Wednesday, reaching $ 21.20 with volume of 559.30 thousand shares. Vericel Corporation has traded high as $ 22.00 and has cracked $ 20.93 on the downward trend
The closing price of $ 21.20, representing a 208.55 % increase from the 52 week low of $ 6.78 and a 6.02 % decrease over the 52 week high of $ 22.26.
The company has a market capital of $ 959.31 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 15th October 2020, maintained by HC Wainwright at Buy rating, with $ 26.00 target price.
- On 12th October 2020, maintained by SVB Leerink at Outperform rating, with $ 30.00 target price.
Conference Call
Vericel Corporation will be hosting a conference call at 8:30 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website vcel.com
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.
